论文部分内容阅读
目的:评价复方难治性非霍奇金淋巴瘤采用氟达拉滨联合表柔比星治疗的临床效果。方法:40例复方难治性非霍奇金淋巴瘤为对照组采用氟达拉滨治疗,35例复方难治性非霍奇金淋巴瘤为研究组采用氟达拉滨联合表柔比星治疗,比较分析不同治疗方法治疗效果以及无病生存率。结果:研究组患者的第4个疗程缓解率优于第1个疗程缓解率,且高于对照组第4个疗程的缓解率,研究组第1年、2年生存率显著优于对照组,P<0.05有统计学意义。结论:复方难治性非霍奇金淋巴瘤患者接受氟达拉滨联合表柔比星治疗,疗效显著。
Objective: To evaluate the clinical efficacy of fludarabine combined with epirubicin in refractory non-Hodgkin’s lymphoma. Methods: Forty patients with refractory non-Hodgkin’s lymphoma treated with fludarabine and 35 patients with refractory non-Hodgkin’s lymphoma were treated with fludarabine combined with epirubicin , Comparative analysis of different treatment methods and treatment-free survival rate. Results: The response rate of the 4th course of treatment was better than that of the 1st course in the study group, and was higher than that of the 4th course of the control group. The first and second year survival rates of the study group were significantly better than those of the control group, P <0.05 was statistically significant. Conclusion: The treatment of patients with refractory non-Hodgkin’s lymphoma received fludarabine combined with epirubicin has a significant effect.